Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 55 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2009 |
| End Date: | August 2015 |
Increasing serum 25OHD from prevailing levels will significantly decrease incidence of all
types of cancer combined in a population sample of healthy postmenopausal women.
The purpose of this study is to determine if vitamin D3 and calcium supplementation
decreases the risk of developing cancer.
types of cancer combined in a population sample of healthy postmenopausal women.
The purpose of this study is to determine if vitamin D3 and calcium supplementation
decreases the risk of developing cancer.
Hypotheses:
Primary: Increasing serum 25OHD from prevailing levels will significantly decrease incidence
of all types of cancer combined in a population sample of healthy postmenopausal women.
Secondary:
1. Increasing serum 25OHD from prevailing levels will significantly decrease incidence of
specific cancers: breast, lung, colon, myeloma, leukemia, lymphoma.
2. Increasing serum 25OHD from prevailing levels will significantly decrease incidence of
other disorders, specifically hypertension, cardiovascular disease, osteoarthritis,
colonic adenomas, diabetes, upper respiratory infections and falls.
Specific Aims:
1. Determine the effect of supplementation with vitamin D3 on incidence of all types of
cancer combined.
2. Determine in a nested-case control study the association of serum 25OHD collected at
randomization and at the end of year one of study with risk of cancer over four years.
3. Sample randomly the population of healthy independently-living postmenopausal women 55
years and older from twelve adjacent rural counties in Nebraska.
4. Enroll a random sample of 2300 women into an intervention study, assign them randomly
to one of two treatment groups: 1) vitamin D3 (2000 IU/d) and calcium (1500 mg/d), or
2) vitamin D3 placebo and calcium placebo, and to follow each study participant for
four years.
5. Collect and store blood serum and white blood cells from every participant to test for
genetic markers should the intervention be found effective in decreasing the incidence
of cancer. Markers selected will be determined by the state of the science at the time
of analysis.
6. Determine the effect of supplementation with calcium and vitamin D3 on incidence of
specific cancers: breast, lung, colon, myeloma, leukemia, and lymphoma.
7. Determine the effect of supplementation on incidence of other disorders, specifically
hypertension, cardiovascular disease, osteoarthritis, colonic adenomas, diabetes, upper
respiratory infections, fractures, and falls.
Primary: Increasing serum 25OHD from prevailing levels will significantly decrease incidence
of all types of cancer combined in a population sample of healthy postmenopausal women.
Secondary:
1. Increasing serum 25OHD from prevailing levels will significantly decrease incidence of
specific cancers: breast, lung, colon, myeloma, leukemia, lymphoma.
2. Increasing serum 25OHD from prevailing levels will significantly decrease incidence of
other disorders, specifically hypertension, cardiovascular disease, osteoarthritis,
colonic adenomas, diabetes, upper respiratory infections and falls.
Specific Aims:
1. Determine the effect of supplementation with vitamin D3 on incidence of all types of
cancer combined.
2. Determine in a nested-case control study the association of serum 25OHD collected at
randomization and at the end of year one of study with risk of cancer over four years.
3. Sample randomly the population of healthy independently-living postmenopausal women 55
years and older from twelve adjacent rural counties in Nebraska.
4. Enroll a random sample of 2300 women into an intervention study, assign them randomly
to one of two treatment groups: 1) vitamin D3 (2000 IU/d) and calcium (1500 mg/d), or
2) vitamin D3 placebo and calcium placebo, and to follow each study participant for
four years.
5. Collect and store blood serum and white blood cells from every participant to test for
genetic markers should the intervention be found effective in decreasing the incidence
of cancer. Markers selected will be determined by the state of the science at the time
of analysis.
6. Determine the effect of supplementation with calcium and vitamin D3 on incidence of
specific cancers: breast, lung, colon, myeloma, leukemia, and lymphoma.
7. Determine the effect of supplementation on incidence of other disorders, specifically
hypertension, cardiovascular disease, osteoarthritis, colonic adenomas, diabetes, upper
respiratory infections, fractures, and falls.
Inclusion Criteria:
- Age: ≥ 55 years
- Last menstrual period (LMP): ≥ 4 years
- Good general health
- Willingness to participate in this 4 year long study
- Able to give informed consent
- Able to live independently and travel to the Fremont Area Medical Center (FAMC) for
study visits
Exclusion Criteria:
- History of cancer except
- Superficial basal or squamous cell carcinoma of the skin
- Other malignancies treated curatively more than 10 years ago
- History of renal calculi or chronic kidney disease
- History of sarcoidosis
- History of tuberculosis
- Participation in the previous Creighton cancer prevention study
- Mini-Mental Status Exam (MMSE) score of ≤ 23. Use the MMSE if there are any concerns
about the person's cognitive abilities or ability to give fully informed consent to
the study. Concerns may be related to a person's lack of orientation to person,
place, or time; language difficulties (inability to structure simple, complete
sentences); or short term memory. The Hartford Institute for Geriatric Nursing
recommends that a score of 23 or lower indicates cognitive impairment. (Accessed at
www.harforddign.org). See appendix.
We found this trial at
1
site
Click here to add this to my saved trials
